Sai Parenterals posts Q4FY26 earnings call audio recording

Sai Parenterals Limited has released the audio recording of its Post Earnings (Group Conference) Call for the quarter and year ended March 31, 2026. The call, held on May 27, 2026, discussed the operational and financial performance of the company. The recording is now available to stakeholders to provide detailed insights into the audited results.

The disclosure was made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The intimation was submitted to both BSE Limited and NSE Limited, with the scrip code 544742 on the former and symbol SAIPARENT on the latter.

Conference Call Details

The earnings call was conducted to review the audited results released on May 23, 2026. Participants had the option to join via DiamondPass to minimize wait times, with specific access numbers provided for domestic and international attendees.

Access Type	Contact Numbers
Primary Access Numbers	+91 22 6280 1488 +91 22 7115 8869
International Toll-Free Numbers	Hong Kong: 800964448 Singapore: 8001012045 UK: 08081011573 US: 18667462133

The audio recording can be accessed at the following link: https://www.saiparenterals.com/announcements/earnings.mpeg . The filing was signed by Mr. Anil Kumar Karusala, Managing Director.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+0.24%	+1.09%	+0.14%	+19.77%	+19.77%	+19.77%

Sai Parenterals Limited has announced its audited financial results for the quarter and year ended March 31, 2026. The company reported a robust performance driven by CDMO exports and the integration of Noumed (Australia). For the full year FY26, the company recorded a Profit After Tax (PAT) of ₹14.37 crore, representing a growth of 45.52% compared to the previous year.

Consolidated Performance

For the financial year ended March 31, 2026, the company reported a revenue of ₹380.99 crore, a significant increase of 140.37% from ₹158.50 crore in FY25. Total income for the year stood at ₹389.51 crore. The company's EBITDA for FY26 was ₹47.21 crore, with a growth of 33.29% year-on-year. The board approved the results during a meeting on May 23, 2026.

Metric	FY26 (₹ Cr)	FY25 (₹ Cr)	YoY Growth
Revenue	380.99	158.50	140.37%
Total Income	389.51	159.14	144.78%
EBITDA	47.21	35.42	33.29%
PAT	14.37	9.87	45.52%
EPS (INR)	4.36	3.71	17.5%

Quarterly Highlights

For the quarter ended March 31, 2026 (Q4 FY26), the consolidated revenue from operations was ₹197.93 crore, a jump of 166.65% compared to Q4 FY25. The net profit for the quarter surged to ₹13.25 crore, up 736.04% from ₹1.59 crore in the corresponding quarter of the previous year. EBITDA for the quarter stood at ₹28.97 crore, growing by 366.79%.

Standalone Results

On a standalone basis, Sai Parenteral's Limited reported a revenue of ₹164.99 crore for FY26, reflecting a growth of 30.65% year-on-year. The standalone PAT for the year was ₹16.86 crore, an increase of 63.61% from the previous year. The company attributed this growth to deeper engagement with customers in export markets.

Business and Strategic Updates

The company highlighted the successful acquisition of a 74.6% controlling stake in Australia-based Noumed Pharmaceuticals Pty Limited on November 12, 2025. This acquisition provides access to 451 dossiers and strengthens the company's position in the Australian market. Additionally, Sai Parenterals successfully completed its IPO in March 2026, raising ₹285 crore, and listed on the exchanges on April 02, 2026. The company is executing a capex program of approximately ₹440 crore, expected to be completed by FY27, to support capacity expansion and R&D.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE0H9F01037/bd15a3ace3764c76.pdf